Plants and the central nervous system

Pharmacology Biochemistry and Behavior

Volumn 75, Issue 3, 2003, Pages 501-512

  Carlini, E A ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Ayahuasca; CNS plants; Ephedra spp.; Guaran ; Iboga; Kava kava; Khat; Medicinal plants; Passiflora; Plant adaptogens; Valeriana

Indexed keywords

ANALGESIC AGENT; ANXIOLYTIC AGENT; BANISTERIOPSIS CAAPI EXTRACT; CANNABIS; CATHA EDULIS EXTRACT; CENTRAL STIMULANT AGENT; EPHEDRA SINICA EXTRACT; KAVA EXTRACT; PASSIFLORA INCARNATA EXTRACT; PAULLINIA EXTRACT; PLANT EXTRACT; PSYCHEDELIC AGENT; PSYCHOTRIA VIRIDIS EXTRACT; TABERNANTHE IBOGA EXTRACT; UNCLASSIFIED DRUG; VALERIAN;

BANISTERIOPSIS CAAPI; CATHA EDULIS; CENTRAL NERVOUS SYSTEM; EPHEDRA SINICA; HUMAN; MEDICINAL PLANT; NONHUMAN; PASSIFLORA INCARNATA; PAULLINIA; PRIORITY JOURNAL; PSYCHOTRIA VIRIDIS; REVIEW; TABERNANTHE IBOGA; VALERIANA;

BANISTERIOPSIS; BANISTERIOPSIS CAAPI; CANNABIS SATIVA; CATHA; CATHA EDULIS; EPHEDRA; PASSIFLORA; PASSIFLORA INCARNATA; PAULLINIA; PAULLINIA CUPANA; PICEA; PIPER METHYSTICUM; PSYCHOTRIA; PSYCHOTRIA VIRIDIS; TABERNANTHE IBOGA; VALERIANA;

EID: 0043199852     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00112-6     Document Type: Review

References (180)

1. Abraham H.D., Aldridge A.M., Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology. 14:1996;285-298.
2. Aceto M.D., Bowman E.R., Harris L.S. Dependence studies of new compounds in the rhesus monkey, rat and mouse. NIDA Res. Monogr. 95:1990;578-631.
3. Airaksinen M.M., Kari I. β-Carbolines, psychoactive compounds in the mammalian body. Part I. Med. Biol. 59:1981;21-34.
4. Airaksinen M.M., Kari I. β-Carbolines, psychoactive compounds in the mammalian body. Part II. Med. Biol. 59:1981;190-211.
5. Almeida R.N., Navarro D.S., Barbosa-Filho J.M. Plants with central analgesic activity. Phytomedicine. 8:2001;310-322.
6. Al-Motarreb A., Baker K., Broadley K.J. Khat: pharmacological and medical aspects and its social use in Yemen. Phytother. Res. 16:2002;403-413.
7. Andreatini R., Leite J.R. Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal. Eur. J. Pharmacol. 260:1994;233-235.
8. Argyropoulos S.V., Nutt D.J. The use of benzodiazepines in anxiety and other disorders. Eur. Neuropsychopharmacol. 9(Suppl. 6):1999;S407-S412.
9. 2 agonists in rats. Pharmacol. Toxicol. 64:1989;165-172.
10. Astrup A., Breum L., Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes. Res. 3(Suppl. 4):1995;537S-540S.
11. Atkinson R.L., Hubbard V.S. Report on the NIH workshop on pharmacologic treatment of obesity. Am. J. Clin. Nutr. 60:1994;153-156.
12. Attele A.S., Wu J.A., Yuan C. Ginseng pharmacology. Biochem. Pharmacol. 58:1999;1685-1693.
13. Avallone R., Zanoli P., Corsi L., Cannazza G., Baraldi M. Benzodiazepine-like compounds and GABA in flower heads of Matricaria chamomilla. Phytother. Res. 10:1996;S177-S179.
14. Baranov A.I. Medicinal use of ginseng and related plants in the Soviet Union: recent trends in the soviet literature. J. Ethnopharmacol. 6:1982;339-353.
15. Barbone F., McMahon A.D., Davey P.G., Morris A.D., Reid I.C., McDevitt D.G.et al. Association of road-traffic accidents with benzodiazepine use. Lancet. 352:1998;1331-1336.
16. Barker S.A.R.E., Harrison J.A., Monti G.B.B., Christian S.T. Identification and quantitation of 1,2,3,4,-tetrahydro-β-carboline, 2-methyl-1,2,3,4,-tetrahydro-β-carboline, and 6-methoxy-1,2,3,4,-tetrahydro-β-carboline as in vivo constituents of rat brain and adrenal gland. Biochem. Pharmacol. 30:1981;9-17.
17. Barnes J., Anderson L.A., Phillipson J.D. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J. Pharm. Pharmacol. 53:2001;583-600.
18. Billia A.R., Gallori S., Vincieri F.F. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci. 70:2002;2581-2597.
19. Blanck H.M., Khan L.K., Serdula M.K. Use of nonprescription weight loss products: results from a multistate survey. JAMA. 286:2001;930-935.
20. Blumenthal M. Kava safety questioned due to case reports of liver toxicity. HerbalGram. 55:2002;26-32.
21. Bombardelli E., Morazzoni P. Hypericum perforatum. Fitoterapia. 66:1995;43-68.
22. Boozer C.N., Nasser J.A., Heymsfield S.B., Wang V., Chen G., Solomon J.L. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int. J. Obes. 25:2001;316-324.
23. Bouldin A.S., Smith M.C., Garner D.D., Szeinbach S.L., Frate D.A., Croom E.M. Pharmacy and herbal medicine in the US. Soc. Sci. Med. 49:1999;279-289.
24. Bray G.A. Obesity, fat intake, and chronic disease. Psychopharmacology. 137:1995;1591-1615.
25. Breckhman I.I., Dardymov I.V. New substances of plant origin which increase nonspecific resistance. Annu. Rev. Pharmacol. 9:1969;419-430.
26. Briskin D.P. Medicinal plants and phytomedicines. Linking plant biochemistry and physiology to human health. Plant Physiol. 124:2000;507-514.
27. Calixto J.B., Beirith A., Ferreira J., Santos A.R.S., Cechinel Filho V., Yunes R.A. Naturally occurring antinociceptive substances from plants. Phytother. Res. 14:2000;401-418.
28. Callaway J.C., Grob C.S. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J. Psychoactive Drugs. 30:1998;367-369.
29. Callaway J.C., Airaksinen M.M., McKenna D.J., Brito G.S., Grob C.S. Platelet serotonin uptake sites increased in drinkers of ayahuasca. Psychopharmacology. 116:1994;385-387.
30. Callaway J.C., Gynther J., Poso A., Vepsäkäinen J., Airaksinen M.M. The Pictet-Spengler reaction and biogenic tryptamines: formation of tetrahydro-β-carbolines at physiological pH. J. Heterocycl. Chem. 31:1994;431-435.
31. Carai M.A.M., Agabio R., Bombardelli E., Bourov I., Gessa G.L., Lobina C.et al. Potential use of medicinal plants in the treatment of alcoholism. Fitoterapia. 71:2000;S38-S42.
32. Carek P.J., Dickerson L.M. Current concepts in the pharmacological management of obesity. Drugs. 57:1999;883-904.
33. Carlini E.A. Efeito adaptógeno ou resistógeno de algumas plantas. Buchillet D. Medicinas tradicionais e medicina ocidental na Amazônia. 1989;45-59 Edições CEJUP, Belém.
34. Casenave S.O.S. Banisteriopsis caapi: ação alucinógena e uso ritual. Rev. Psiquiat. Clín. 1:2000;32-35.
35. Chantre P., Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine. 9:2002;3-8.
36. Costa O.A., Faria L. A planta que faz sonhar - O Yage. Rev. Flora Med. 2:1936;575-624.
37. Craig W.J. Phytochemicals: guardians of our health. J. Am. Diet Assoc. 97(Suppl. 2):1997;S199-S204.
38. Davydov M., Krikorian A.D. Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. (Araliaceae) as an adaptogen: a closer look. J. Ethnopharmacol. 72:2000;345-393.
39. De Sio F. Notes on the research of ibogaine, used as a doping factor. Med. Sport. 23:1970;362-363.
40. De Smet P.A.G.M. Some ethnopharmacological notes on African hallucinogens. J. Ethnopharmacol. 50:1996;141-146.
41. De Smet P.A.G.M. The role of plant-derived drugs and herbal medicines in healthcare. Drugs. 54:1997;801-840.
42. Delay J., Deniker P. Methods chimiothérapiques en psychiatrie: les nouveaux medicaments psychotropes. 1961;Masson et Cie, Paris.
43. 2 receptors. Biochem. Pharmacol. 41:1991;1739-1744.
44. Deltito J., Beyer D. The scientific, quasi-scientific and popular literature on the use of St. John's wort in the treatment of depression. J. Affect. Disord. 51:1998;345-351.
45. Denham A., McIntyre M., Whitehouse J. Kava - the unfolding story: report on a work-in-progress. J. Altern. Complement Med. 8:2002;237-263.
46. Dhawan K., Kumar S., Sharma A. Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. J. Ethnopharmacol. 78:2001;165-170.
47. Dhuley J.N. Adaptogenic and cardioprotective action of ashwagandha in rats and frogs. J. Ethnopharmacol. 70:2000;57-63.
48. Dhuley J.N. Nootropic-like effect of ashwagandha (Withania sonnifera L.) in Mice. Phytother. Res. 15:2001;524-528.
49. Dilsaver S.C. Antimuscarinic agents as substances of abuse: a review. J. Clin. Psychopharmacol. 8:1988;14-22.
50. Dossaji S.F., Wrangham R., Rodriguez E. Selection of plants with medicinal properties by wild chimpanzees. Fitoterapia. 60:1989;378-380.
51. Dulloo A.G. Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int. J. Obes. Relat. Metab. Disord. 17(Suppl. 1):1993;S35-S40.
52. Dzoljic E.D., Kaplan C.D., Dzoljic M.R. Effect of ibogaine on naloxone precipitated withdrawal syndrome in chronic morphine dependent rats. Arch. Int. Pharmacodyn. Ther. 294:1988;64-70.
53. Eisenberg D.M., Kessler R.C., Foster C., Norlock F.E., Calkins D.R., Delbanco T.L. Unconventional medicine in the United States. N. Engl. J. Med. 328:1993;246-252.
54. Elvin-Lewis M. Should we be concerned about herbal remedies. J. Ethnopharmacol. 75:2001;141-164.
55. Emboden W. Narcotic plants. 1972;Studio Vista, London.
56. Espínola E.B., Dias R.F., Mattei R., Carlini E.A. Pharmacological activity of guaraná (Paullinia cupana Mart.) in laboratory animals. J. Ethnopharmacol. 55:1997;223-229.
57. Farnsworth N.R. Hallucinogenic plants. Science. 162:1968;1086-1092.
58. Fellow E.J., Smith C.S. The chemistry of Passiflora incarnata. J. Am. Pharm. Assoc. 27:1938;565-573.
59. Fulder S. The drug that builds Russians. New Sci. 87:1980;576-579.
60. Gill N.D., Shield A., Blazevich A.J., Zhou S., Weatherby R.P. Muscular and cardiorespiratory effects of pseudoephedrine in human athletes. Br. J. Clin. Pharmacol. 50:2000;205-213.
61. Gillis C.N. Panax ginseng pharmacology: a nitric oxide link? Biochem. Pharmacol. 54:1997;1-8.
62. Glennon R.A., Young R. (+) Amphetamine-stimulus generalization to an herbal ephedrine product. Pharmacol. Biochem. Behav. 65:2000;655-658.
63. Glenny A.M., O'Meara S., Melville A., Sheldon T.A., Wilson C. The treatment and prevention of obesity: a systematic review of the literature. Int. J. Obes. Relat. Metab. Disord. 21:1997;715-737.
64. Glick S.D., Rossman K., Steindorf S., Maisonneuve I.M., Carlson J.N. Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol. 195:1991;341-345.
65. Glick S.D., Rossman K., Rao N.C., Maisonneuve I.M., Carlson J.N. Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology. 31:1992;497-500.
66. Grella B., Dukat M., Young R., Teitler M., Herrick-Davis K., Gauthier C.B.et al. Investigation of hallucinogenic and related β-carbolines. Drug Alcohol. Depend. 50:1998;99-107.
67. Grob C.S., McKenna D.J., Callaway J.C., Brito G.S., Neves E.S., Oberlaender G.et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J. Nerv. Ment. Dis. 184:1996;86-94.
68. Grunze H., Langosch J., Schirrmacher K., Bingmann D., Von Wegerer J., Walden J. Kava pyrones exert effects on neuronal transmission and transmembraneous cation currents similar to established mood stabilizers - a review. Prog. Neuropsychopharmacol. Biol. Psychiatry. 25:2001;1555-1570.
69. Habs M. Herbal products: advances in preclinical and clinical development. Drug Inf. J. 33:1999;993-1001.
70. Han L.K., Takaku T., Li J., Kimura Y., Okuda H. Anti-obesity action of oolong tea. Int. J. Obes. Relat. Metab. Disord. 23:1999;98-105.
71. Han L.K., Kimura Y., Kawashima M., Takaku T., Taniyama T., Hagashi T.et al. Anti-obesity effects in rodents of dietary teasaponin, a lipase inhibitor. Int. J. Obes. Relat. Metab. Disord. 25:2001;1459-1464.
72. Hancke J.L., Burgos R.A., Ahumada F. Schisandra chinensis (Turcz.) Baill. Fitoterapia. 70:1999;451-471.
73. Herrera-Arellano A., Luna-Villegas G., Cuevas-Uriostegui M.L., Alvarez L., Vargas-Pineda G., Zamilpa-Alvarez A.et al. Polysomnographic evaluation of the hypnotic effect of Valeriana edulis standardized extract in patients suffering from insomnia. Planta Med. 67:2001;695-699.
74. Herridge C.F., A'Brook M.F. Ephedrine psychosis. BMJ. 2:1968;160.
75. Hippius H. St John's wort (Hypericum perforatum) - a herbal antidepressant. Curr. Med. Res. Opin. 14:1998;171-184.
76. Hofmann A. Ololiuqui: a sacred drug of the Aztecs. Pharm. Int. 3:1982;216-217.
77. Holmstedt B., Fredga A. Sundry episodes in the history of coca and cocaine. J. Ethnopharmacol. 3:1981;113-147.
78. Holmstedt B., Lindgren J.-E. Ethnopharmacologic search for psychoactive drugs. 1967;U.S. Government Printing Office, Washington.
79. Houghton P.J. The scientific basis for the reputed activity of valerian. J. Pharm. Pharmacol. 51:1999;505-512.
80. Hua X.-Y., Chen P., Hwang J., Yaksh T.L. Antinociception induced by civamide, an orally active capsaicin analogue. Pain. 71:1997;313-322.
81. Jamieson D.D., Duffield P.H., Cheng D., Duffield A.M. Comparison of the central nervous system activity of the aqueous and lipid extract of kava (Piper methysticum). Arch. Int. Pharmacodyn. 301:1989;66-80.
82. Johanson C., Fischman M.W. The pharmacology of cocaine related to its abuse. Pharmacol. Rev. 41:1989;3-52.
83. 2 receptor in rat frontal cortex. Pharmacol. Biochem. Behav. 35:1990;211ff.
84. Jonas W.B. Alternative medicine - learning from the past, examining the present, advancing the future. JAMA. 280:1998;1616-1618.
85. Kan C.C., Breteler M.H.M., Zitman F.G. High prevalence of benzodiazepine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria. Acta Psychiatr. Scand. 96:1997;85-93.
86. Karch S.B. Cocaine: history, use, abuse. J. R. Soc. Med. 92:1999;393-397.
87. Kelly G.S. Rhodiola rosea: a possible plant adaptogen. Altern. Med. Rev. 6:2001;293-302.
88. Kovera CA, Kovera MB, Singleton EG, Ervin FR, Williams IC, Mash DC. Decreased drug craving during inpatient detoxification with ibogaine [on line]. Available at: http://www.erowid.org/chemicals/ibogaine/ibogaine_journal2.shtml; 2001.
89. Kuezinarski R.J. Prevalence of overweight and weight gain in the United States. Am. J. Clin. Nutr. 55:1992;495S-502S. [suppl].
90. Labigalini EJ. O uso de ayhuasca em um contexto religioso por ex-dependentes de álcool - um estudo qualitativo. Master of Sciences Thesis, Federal University of São Paulo; 1998. p. 1-67.
91. Labigalini EJ, Miranda C, Tacla C. O uso ritualizado de ayahuasca: alternativa terapeutica para alcoolismo. Resumo - Seminário International O Uso e o Abuso de Drogas - CETAD/UFBa, Salvador 107-107; 1995.
92. Lader M., Morton S. Benzodiazepine problems. Br. J. Addict. 86:1991;823-828.
93. Lazarev N.V. 7th All-Union Congress of Physiology, Biochemistry and Pharmacology; Medgiz, Moscow. 1947;579. Apud: Wagner et al., 1994.
94. Leal M.B., Emanuelli T., Porciúncula L.O., Souza D.O., Elisabetsky E. Ibogaine alters synaptosomal and glial glutamate release and uptake. Neuroreport. 12:2001;263-267.
95. Leathwood P.D., Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med. 51:1985;144-148.
96. Leathwood P.D., Chauffard F., Heck E., Munoz-Box R. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol. Biochem. Behav. 17:1982;65-71.
97. Lindahl O., Lindwall L. Double blind study of a valerian preparation. Pharmacol. Biochem. Behav. 32:1989;1065-1066.
98. Liwszyc G.E., Vuori E., Rasanen I., Issakainen J. Daime - a ritual herbal potion. J. Ethnopharmacol. 36:1992;91-92.
99. Lleras E. Species of Paullinia with economic potential [on line]. Available at: http://www.hort.purdue.edu/newcrop/1492/paullinia.html;2002.
100. Lopes C. A propósito das toxicomanias raras ou menos freqüentes entre nós. Arch. Bras. Hyg. Ment. 7:1934;111-119.
101. Maisonneuve I.M., Visker K.E., Mann G.L., Bandarage U.K., Kuehne M.E., Glick S.D. Time-dependent interactions between iboga agents and cocaine. Eur. J. Pharmacol. 336:1997;123-126.
102. Maisonneuve I.M., Mann G.L., Deibel C.R., Glick S.D. Ibogaine and the dopaminergic response to nicotine. Psychopharmacology. 129:1997;249-256.
103. Malsch U., Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology. 157:2001;277-283.
104. Marken P.A., Stoner S.C., Bunker M.T. Anticholinergic drug abuse and misuse. CNS Drugs. 5:1996;190-199.
105. Martinet A., Hostettmann K., Schutz Y. Thermogenic effects of commercially available plant preparations aimed at treating human obesity. Phytomedicine. 6:1999;231-238.
106. Mash D.C. Development of ibogaine as an anti-addictive drug: a progress report from the university of Miami School of Medicine. Newsl. Multidiscip. Assoc. Psychoact. Subst. (MAPS). 6:1995;29-30.
107. Mash DC, Allen-Ferdinand K, Mayor M, Kovera CA, Ayafor JF, Williams, IC, et al. Clinical observations of safety after single oral dose administration [on line]. Available at: http://www.erowid.org/chemicals/ibogaine/ibogaine_journal1.shtml; 2001.
108. Mattei R., Dias R.F., Espínola E.B., Carlini E.A., Barros S.B.M. Guaraná (Paullinia cupana): toxic behavioral effects in laboratory animals and antioxidant activity in vitro. J. Ethnopharmacol. 60:1998;111-116.
109. 3H-ketanserin. J. Neurosci. 9:1989;3482-3490.
110. McKenna D., Towers G.H.N., Abbott F.S. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca. J. Ethnopharmacol. 10:1984;195-223.
111. McKenna D.J., Repke D.B., Lo L., Peroutka S.J. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology. 29:1990;193-198.
112. Mendes F., Mattei R., Carlini E.A. Activity of Hypericum brasiliense and Hypericum cordatum on the central nervous system in rats. Fitoterapia. 73:2002;462-471.
113. Molnar D., Török K., Erhardt E., Jeges S. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. Int. J. Obes. Relat. Metab. Disord. 24:2000;1573-1578.
114. Morazzoni P., Bombardelli E. Valeriana officinalis: traditional use and recent evaluation of activity. Fitoterapia. 66:1995;99-112.
115. Moro C.O., Basile G. Obesity and medicinal plants. Fitoterapia. 71:2000;S73-S82.
116. Morris K. Data accrue on "visionary" agent to interrupt addiction. Lancet. 354:1999;1883.
117. Mors W.B., Rizzini C.T., Pereira N.A. Medicinal plants of Brazil. 2000;Reference Publications, Michigan.
118. Müller J.L. Love potions and the ointment of witches: historical aspects of the nightshade alkaloids. Clin. Toxicol. 36:1998;617-627.
119. Münte T.F., Heinze H.J., Matzke M., Steitz J. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology. 27:1993;46-53.
120. Murase T., Nagasawa A., Suzuki J., Hase T., Tokimitsu I. Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver. Int. J. Obes. Relat. Metab. Disord. 26:2002;1459-1464.
121. Nappo S.N., Carlini E.A. Anoréticos: situação atual no Brasil. Arq. Bras. Endocrinol. Metabol. 38:1994;69-75.
122. Naranjo C. Psychotherapeutic possibilities of new fantasy-enhancing drugs. Clin. Toxicol. 2:1969;209-224.
123. Nencini P., Ahmed A.M., Elmi A.S. Subjective effects of khat chewing in humans. Drug Alcohol. Depend. 18:1986;97-105.
124. Nogueira E., Rosa G.J.M., Haraguchi M., Vassilieff V.S. Anxiolytic effect of Rubus brasilensis in rats and mice. J. Ethnopharmacol. 61:1998;111-117.
125. A-benzodiazepine receptor in the anxiolytic effect induced by hexanic fraction of Rubus brasilensis. J. Ethnopharmacol. 61:1998;119-126.
126. Norton A.S., Ruze P. Kava dermopathy. J. Am. Acad. Dermatol. 31:1994;89-97.
127. Nwosu M.O. Herbs for mental disorders. Fitoterapia. 70:1999;58-63.
128. O'Hearn E., Molliver M.E. Degeneration of Purkinje cells in parasagital zones of the cerebellar vermis after treatment with ibogaine and harmaline. Neuroscience. 55:1993;303-310.
129. Ott J. Pharmahuasca: human pharmacology of oral DMT plus harmine. J. Psychoactive Drugs. 31:1999;171-177.
130. Panossian A., Gabrielian E., Wagner H. Plant adaptogens: II. Bryonia as an adaptogen. Phytomedicine. 4:1997;85-99.
131. Panossian A., Wikman G., Wagner H. Plant adaptogens: III. Earlier and more recent aspects and concepts on their mode of action. Phytomedicine. 6:1999;287-300.
132. Pepping J. Kava: Piper methysticum. Am. J. Health-Syst. Pharm. 56:1999;957-963.
133. Petry R.D., Reginatto F., de-Paris F., Gosmann G., Salgueiro J.B., Quevedo J.et al. Comparative pharmacological study of hydroethanol extracts of Passiflora alata and Passiflora edulis leaves. Phytother. Res. 15:2001;162-164.
134. Phillipson J.D. Phytochemistry and medicinal plants. Phytochemistry. 56:2001;237-243.
135. Pierfitte C., Macouillard G., Thicoïpe M., Chaslerie A., Pehourcq F., Aïssou M.et al. Benzodiazepines and hip fractures in elderly people: case-control study. BMJ. 322:2001;704-708.
136. Pomilio A.B., Vitale A.A., Ciprian-Ollivier J., Cetkovich-Bakmas M., Gómez R., Vázquez G. Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia. J. Ethnopharmacol. 65:1999;19-51.
137. Popik P., Layer R.T., Skolnick P. 100 years of Ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol. Rev. 47:1995;235-253.
138. Poston W.S.C. II, Foreyt J.P., Borrell L., Haddock K. Challenges in obesity management. South. Med. J. 91:1998;710-720.
139. Poyares D.R., Guilleminault C., Ohayon M.M., Tufik S. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal? Prog. Neuropsychopharmacol. Biol. Psychiatry. 26:2002;539-545.
140. Rates S.M.K. Plants as source of drugs. Toxicon. 39:2001;603-613.
141. Rege N.N., Thatte U.M., Dahanukar S. Adaptogenic properties of six rasayana herbs used in ayurvedic medicine. Phytother. Res. 13:1999;275-291.
142. Rios J.L., Simeon S., Villar A. Pharmacological activity of aporphinoid alkaloids. A review. Fitoterapia. 60:1989;387-413.
143. Sanchez-Ramos J., Mash D. Ibogaine research update: phase 1 human study. Newsl. Multidiscip. Assoc. Psychoact. Subst. (MAPS). 4:1994;11.
144. Schneider J.A., Sigg E.B. Neuropharmacological studies on ibogaine, an indole alkaloid with central stimulant properties. Ann. N. Y. Acad. Sci. 66:1957;765-766.
145. Schneider-Helmert D. Why low-dose benzodiazepine-dependent insomniacs can't escape their sleeping pills. Acta Psychiatr. Scand. 78:1988;706-711.
146. Schultes R.E. The virgin field in psychoactive plant research. Bol. Mus. Para. Emílio Goeldi, Bot. 6:1990;6-83.
147. Schultes R.E., Hofmann A. Plants of the gods: origins of hallucinogenic use. 1979;EMB - Service for Publishers, Lucerne.
148. Schultes R.E., Holmstedt B. De plantis toxicariis e mundo novo tropicale commentationes II. Rhodora. 70:1968;113-160.
149. Schweizer E., Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr. Scand. 98(Suppl. 393):1998;95-101.
150. Selye H. Studies on adaptation. Bull. Assoc. Study Int. Secret. 21:1937;169-188.
151. Selye H. Experimental evidence supporting the conception of "adaptation energy" Am. J. Physiol. 123:1938;758-765.
152. Sershen H., Hashim A., Lajtha A. Ibogaine reduces preference for cocaine consumption in C57BL/6By mice. Pharmacol. Biochem. Behav. 47:1994;13-19.
153. Shulgin A, Shulgin A. Tihkal the Continuation: 25-ibogaine [on line]. Available at: http://www.erowid.org/library/books_online/tihkal/tihkal25.shtml; 2001.
154. Silverstone T. Appetite suppressants - a review. Drugs. 43(6):1992;820-836.
155. Singh Y.N. Kava: an overview. J. Ethnopharmacol. 37:1992;13-45.
156. Singh B., Saxena A.K., Chandan B.K., Gupta D.K., Bhutani K.K., Anand K.K. Adaptogenic activity of a novel, withanolide-free aqueous fraction from the roots of Withania somnifera Dun. Phytother. Res. 15:2001;311-318.
157. Soleimani R., Younos C., Jarmouni S., Bousta D., Misslin R., Mortier F. Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. J. Ethnopharmacol. 57:1997;11-20.
158. Speroni E., Billi R., Mercati V., Boncompagni E., Toja E. Sedative effects of crude extract of Passiflora incarnata after oral administration. Phytother. Res. 10:1996;S92-S94.
159. Speroni E., Billi R., Perellino N.C., Minghetti A. Role of Chrysin in the sedative effects of Passiflora incarnata L. Phytother. Res. 10:1996;S98-S100.
160. Strassman R.J. Human psychopharmacology of N,N-dimethyltryptamine. Behav. Brain Res. 73:1996;121-124.
161. Szumlinski K.K., Maisonneuve I.M., Glick S.D. Ibogaine enhances the expression of locomotor sensitization in rats chronically treated with cocaine. Pharmacol. Biochem. Behav. 63:1999;457-464.
162. Szumlinski K.K., Maisonneuve I.M., Glick S.D. Pretreatment with the putative anti-addictive drug, ibogaine, increases the potency of cocaine to elicit locomotor responding: a study with acute and chronic cocaine-treated rats. Psychopharmacology. 145:1999;227-233.
163. Szumlinski K.K., Maisonneuve I.M., Glick S.D. Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine. Eur. J. Pharmacol. 398:2000;259-262.
164. Theoharides T.C. Sudden death of a health college student related to ephedrine toxicity from a Ma Huang-containing drink. J. Clin. Psychopharmacol. 17:1997;437-439.
165. Tihonen J., Kuikka J., Rasänen P., Lepola U., Koponen H., Liuska A.et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol. Psychiatry. 2:1997;463-471.
166. Uhlenhuth E.H., Balter M.B., Ban T.A., Yang K. Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992-1997. Eur. Neuropsychopharmacol. 9(Suppl. 6):1999;S393-S398.
167. 450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med. 68:2002;1055-1058.
168. Viola H., Wasowski C., Stein L., Wolfman C., Silveira D., Dajas F.et al. Apigenin a component of Matricaria recutita flowers, is a central benzodiazepine receptor-ligand with anxiolytic effect. Planta Med. 61:1995;213-216.
169. Vogler B.K., Pittler M.H., Ernst E. The efficacy of ginseng. A systematic review of randomized clinical trials. Eur. J. Clin. Pharmacol. 55:1999;567-575.
170. Wagner H. Leading structures of plant origin for drug development. J. Ethnopharmacol. 38:1993;105-112.
171. Wagner H., Nörr H., Winterhoff H. Plant Adaptogens. Phytomedicine. 1:1994;63-76.
172. Whiskey E., Werneke U., Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int. Clin. Psychopharmacol. 16:2001;239-252.
173. Whitehouse A.M. Ephedrine psychosis rediscovered. Br. J. Psychiatry. 150:1987;258-261.
174. Winter J.C., Rabin R.A. Interactions between serotonergic agonists and antagonists in rats trained with LSD as a discriminative stimulus. Pharmacol. Biochem. Behav. 30:1988;617-624.
175. WHO monographs on selected medicinal plants: Radix valerianae. vol. 1:1999;267-276 WHO, Geneva, Switzerland.
176. Wong A.H.C., Smith M., Boon H.S. Herbal remedies in psychiatric practice. Arch. Gen. Psychiatry. 55:1998;1033-1044.
177. Yanovski S.Z., Yanovski J.A. Obesity. N. Engl. J. Med. 346:2002;591-602.
178. Zelger J.L., Carlini E.A. Anorexigenic effects of two amines obtained from Catha edulis Forsk (khat) in rats. Pharmacol. Biochem. Behav. 12:1980;701-705.
179. 3H]dopamine in striatal slices of rats. Neuropharmacology. 20:1981;839-843.
180. Zelger J.L., Schorno H.X., Carlini E.A. Behavioural effects of cathinone, an amine obtained from Catha edulis Forsk: comparisons with amphetamine, norpseudoephedrine, apomorphine and nomifensine. Bull. Narc. 32:1980;67-81.